Showing 2691-2700 of 3329 results for "".
- Dr. Michelle Henry Highlights Noninvasive Periorbital Rejuvenationhttps://modernaesthetics.com/news/dr-michelle-henry-highlights-noninvasive-periorbital-rejuvenation/2483904/Understanding facial aging patterns specific to richly pigmented skin and adjusting treatment approaches accordingly, especially as patient preferences shift away from traditional lower eyelid filler, is key in managing periorbital aging in patients with skin of color, Michelle Henry, MD, FAAD, s
- Sciton Launches Multi-Wavelength Resurfacing Laser Platformhttps://modernaesthetics.com/news/sciton-launches-multi-wavelength-resurfacing-laser-platform/2483427/Sciton, Inc. has introduced HALO® TRIBRID™, a laser platform that integrates 3 wavelengths—2940 nm, 1927 nm, and 1470 nm—into a single resurfacing device. The system combines the company’s previously distinct technologies (HALO®, MOXI™, and Erbium Resurfacing) into one handpiece, allowing provide
- Hugel Marks 15 Years of Letybo with 2025 H.E.L.F Symposium in Seoulhttps://modernaesthetics.com/news/hugel-marks-15-years-of-letybo-with-2025-helf-symposium-in-seoul/2483385/More than 220 medical professionals from across the globe gathered in Seoul on September 14 for Hugel Inc.’s 2025 H.E.L.F. symposium, marking 15 years since the launch of its botulinum toxin, Letybo. The Hugel Expert Leader’s Forum was held at Seoul Dragon City under the theme, “K-Beau
- Neuvian Skincare Granted US Patent for Dual-Peptide Complexhttps://modernaesthetics.com/news/neuvian-skincare-granted-us-patent-for-dual-peptide-complex/2483373/Neuvian Skincare has received a US patent for its dual-peptide formulation targeting inflammatory skin conditions such as wounds, scars, and eczema, according to a press release. The patent (No. 12,377,156 B2), issued for “Compositions and Methods for Treatment of Wounds and Inflammatory Skin Con
- Oral GLP-1 Hits Phase 3 Trial Targets; Regulatory Submissions Cominghttps://modernaesthetics.com/news/oral-glp-1-hits-phase-3-trial-targets-regulatory-submissions-coming/2483149/Eli Lilly and Company announced positive topline results from its Phase 3 ATTAIN-2 trial, showing that its investigational oral GLP-1 receptor agonist, orforglipron, achieved significant weight loss and improved cardiometabolic outcomes in adults with obesity or overweight status and type 2 diabe
- Korean Skincare Brand Launches in US with Sensitive-Skin Formulationshttps://modernaesthetics.com/news/korean-skincare-brand-launches-in-us-with-sensitive-skin-formulations/2483054/South Korean skincare brand Hexkin has entered the US market, offering products formulated for sensitive skin using collagen-based and peptide-driven technologies, according to a press release. Rooted in traditional Korean sk
- New Website Streamlines Laser Therapy Device Selectionhttps://modernaesthetics.com/news/new-website-streamlines-laser-therapy-device-selection/2482984/ColdLasers.org has launched LaserTherapy.com, a redesigned platform aimed at simplifying the process of selecting therapeutic laser devices. The site offers a modern interface, comparison tools, and updated educational content designed to support informed decision-making. The platform addr
- JUVÉDERM Day Returns with Limited-Time Offers Through Rewards Programhttps://modernaesthetics.com/news/juvederm-day-returns-limited-time-offers-through-rewards-program/2482957/Members of JUVÉDERM’s Alle loyalty rewards program will have an opportunity to purchase “buy one, get one” gift cards as part of JUVÉDERM Day on August 20, according to Allergan Aesthetics, an AbbVie company. Details of the exclusive, limited limited-time offers are as follows: •
- Noninvasive Brain Stimulation for Mental Wellness Coming to Illinois Dermatology Clinichttps://modernaesthetics.com/news/noninvasive-brain-stimulation-mental-wellness-coming-illinois-dermatology-clinic/2482956/An Illinois dermatology clinic is now offering a noninvasive brain stimulation treatment for patients experiencing depression, anxiety, and related mental health concerns. Dundee Dermatology recently introduced EXOMIND, a transcranial magnetic stimulation (TMS) device that is FDA
- Regenerative Dermatology Company Forms Strategic Manufacturing Partnership with Innovigenhttps://modernaesthetics.com/news/regenerative-dermatology-company-forms-strategic-manufacturing-partnership-with-innovigen/2476008/Robles BioCeutics, a regenerative dermatology company focused on senolytic and stem cell-powered skincare, has entered a strategic manufacturing partnership with Innovigen, a California-based formulation and production company specializing in cosmetic GMP manufacturing. The agreement represents a